Overview

A Randomised Trial to Evaluate Toxicity and Efficacy of 1200mg and 1800mg Rifampicin for Pulmonary Tuberculosis

Status:
Active, not recruiting

Trial end date:
2022-04-30

Target enrollment:

Participant gender:

Summary

In this trial, the investigators are assessing whether giving an increased dose of rifampicin to patients receiving the standard treatment for tuberculosis is safe and, when given for 4 months only, will also result in greater and faster killing of the tubercle bacillus in the lungs and result in relapse rates similar to those found in the World Health Organisation (WHO) recommended standard 6 month regimen.

Phase:

Phase 3

Details

Lead Sponsor:

St George's, University of London

Collaborators:

London School of Hygiene and Tropical Medicine
University of Botswana

Treatments:

Ethambutol
Isoniazid
Pyrazinamide
Rifampin